Bristol Myers cuts mid-stage NASH, anti-TIGIT programs

Bristol Myers Squibb disclosed Thursday at its R&D Day that it cut six programs, including mid-stage drug candidates for NASH and solid tumors.

The New Jersey pharma company axed an siRNA for NASH, known as HSP47, which it licensed from Nitto Denko for $100 million upfront…
Click here to view original post